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Because the size of renal cysts in the native kidneys of
patients with ADPKD who have been transplanted was found
to be reduced when rapamycin was the immunosuppressant,
we tested the involvement of the mTOR pathway in cyst
enlargement. Here, male pcy mice, with mutation in one of
the nephronophthisis genes, were treated with rapamycin at
an early (6 to12 weeks of age) or a later (20 to 30 weeks of
age) disease stage by means of slow-release pellets
containing placebo or rapamycin. Effectiveness of the
rapamycin dose and delivery was shown by the inhibition of
insulin-stimulated phosphorylation of p70S6K, a marker of
mTOR activity, in skeletal muscle. Early treatment did not
affect initial cyst development but when started late, there
was a significant reduction in the rate of cyst enlargement,
kidney fibrosis, and the progressive loss of renal function as
measured by blood urea nitrogen. Kidneys of the mice
treated through 30 weeks of age tended to be smaller and
have less fibrosis compared with those of untreated or
placebo-treated pcy/pcy mice at 20 weeks when treatment
was initiated. Our study shows that rapamycin can prevent
the late- but not the early-stage progression of renal
pathology and deterioration of renal functional in this model
of nephronophthisis, presumably by inhibiting mTOR activity.
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Nephronophthisis (NPHP) is part of a group of autosomal
recessive conditions caused by mutations in one of six (or
more, NPHP1-NPHP6) genes, similarly characterized by the
presence of renal cysts with tubulointerstitial fibrosis.1 NPHP
is one of the hepatorenal fibrocystic conditions that also
include; polycystic kidney diseases, Bardet-Beidl syndrome,
Meckel-Gruber Syndrome, and Oral-Facial Digital Syn-
drome. NPHP is a leading cause of renal demise in the first
three decades of life. Although the kidney is the major organ
of interest in this condition, numerous other organs can be
involved including: the liver (which can become fibrotic), eye
(in Senior-Loken Syndrome), and brain (in Joubert Syn-
drome). The protein products of all of the NPHPs seem to
localize to cilia;1 however, the exact mechanism involved in
the pathogenesis of these renal conditions are not well
understood, but some data suggest that the cells are not
correctly perceiving or responding to extracellular or
environmental cues. The cellular pathways that have been
implicated in the pathogenesis of these renal disorders
include: G-protein-linked receptor stimulated cyclic AMP,
altered cellular calcium and the mammalian target of
rapamycin (mTOR) pathway.2
This study evaluated the possible involvement of the
mTOR pathway in a murine model of NPHP using the
mTOR inhibitor rapamycin (sirolimus). The murine pcy gene
is orthologous to the human NPHP3 gene that causes
adolescent NPHP.3,4 The pcy mouse develops renal pathol-
ogy5 that is similar to that seen in NPHP. This model has
been useful in evaluating other pathways that contribute to
renal cystic conditions.6 There is no treatment, at present, for
NPHP, and as rapamycin is already available, we hoped to
determine if mTOR inhibition is efficacious at inhibiting the
initial development of renal cystic pathology and/or inhibit-
ing the progression of the renal pathology and/or renal
functional decline associated with this condition and other
renal cystic diseases.
Rapamycin (or other mTOR inhibitors) has been shown
to ameliorate the initial progression of renal cystic change in
three non-orthologous rodent models of hepatorenal fibro-
cystic disease (the Cy/þ rat,7–9 the bpk, and orpk mice10). In
addition, renal transplant patients with autosomal dominant
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polycystic kidney disease (ADPKD) had less renal enlarge-
ment if rapamycin was part of their anti-rejection drug
regimen10 as well as a reduced liver volume.11 These data
clearly suggest that the mTOR pathway is involved in the
progression of the renal cystic pathology. The mTOR
pathways’ activity potentially leads to the activation
of the MEK–ERK pathway causing proliferation. Data from
Omori et al.12 found that the MEK–ERK pathway was
increased in the pcy mouse. This study evaluated develop-
mental aspects of mTOR activity and the efficacy of mTOR
pathway inhibition in an orthologous model of human
adolescent NPHP.
RESULTS
The cystic kidney of CD1-pcy mice with adolescent NPHP
have elevated total Akt at 30 weeks and prominently elevated
phosphorylated Akt at 12 and 30 weeks of age (Figure 1a
and b). Akt is part of the pathways associated with activating
mTOR. Thus, conditions are primed for mTOR activation.
The best assessment of mTOR activity is the phosphorylation
of p70S6K.13 Total p70S6K is elevated in the cystic kidney at
12 and 30 weeks of age, whereas the proportion of
phosphorylated p70S6K is slightly elevated at 4 weeks (over
that seen in wild-type CD1 kidneys) with an age related
increase at 12 and 30 weeks of age (Figure 1c and d). The very
elevated (eightfold) P-p70S6K at 30 weeks is indicative of a
strongly activated mTOR pathways. As with all form of PKD,
phosphorylated ERK is elevated but rather uniformly across
all ages as compared with wild-type CD1 mice (Figure 1e),
suggesting that factors other than mTOR may be playing a
stronger role early in the disease process.
Male CD1-pcy mice were treated with slow-release pellets
containing rapamycin, which was released at an approximate
rate of 3 mg/kg-bw/day. Treatment from 6 weeks of age to 12
weeks of age had no discernable effect on progression of the
renal cystic disease during this early phase of the disease. The
degree of renal enlargement between 6 weeks and 12 weeks
was equivalent in both rapamycin and control groups
(Table 1), suggesting that mTOR is not significantly involved
in the initial cystic renal enlargement in murine adolescent
NPHP. However, treatment from 20 to 30 weeks of age was
efficacious in inhibiting the further renal cystic enlargement
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Figure 1 | Graphic representation of expression by western blot of Akt, p70S6K, and ERK in the pcy mouse kidney.
(a and b) Total and phosphorylated Akt, which is upstream of mTOR activation. Total Akt protein in cystic kidney (open bars) is compared
with comparably aged wild-type CD1 mice (black bars set at 100%) showing a dramatic increase in the cystic kidney at 30 weeks of age
and the proportion of phosphorylated Akt is increased at both 12 and 30 weeks of age. (c and d) Total and phosphorylated p70S6K, which is
downstream of mTOR and generally accepted as reflecting the activity of mTOR. Total p70S6K protein is increased in the cystic kidney (open
bars) at both 12 and 30 weeks (normalized to age-matched wild-type controls, black bars). And phosphorylated p70S6K is increased in the
cystic kidney at all ages, but is especially prominent late in the disease. (e) Phosphorylated ERK is elevated at all ages in the cystic kidney as
has generally been found in all of the murine models of renal cystic disease. Bars (left to right) represent n¼ 2, 3, 2, 2, 2 ,3.
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and deterioration of renal function (Table 1). The renal
pathology in the 30-week control group was generally
increased compared with the 20-week control, whereas the
30-week rapamycin-treated group was less severely affected
compared with the 30-week control group (Figure 2). The
30-week histological specimens were evaluated for mitosis
and apoptosis in the cystic epithelial cells. Whereas there was
a slight tendency for decreased cystic epithelial cell prolifera-
tion in the rapamycin-treated mice, there were no significant
differences between rapamycin and control kidney (mitotic
index (%), rapamycin vs control, 0.15%±0.15 vs 0.50%±
0.15 and apoptosis (%) 3.10%±0.67 vs 2.45%±0.63). The
use of rapamycin was effective in halting the progression of
the histopathology and renal functional deterioration in this
later stage of the disease. The kidneys in the rapamycin-
treated group were actually smaller (when expressed as a
percentage of total body weight) than those of the 20-week
control group, whereas total body weight was not different,
Table 1 | Efficacy of rapamycin treatment
Group
6-Week control
(n=6)
12-Week control
(n=14)
6–12-Week
rapamycin (n=7)
20-Week control
(n=5)
30-Week control
(n=10)
20–30-Week
rapamycin (n=5)
BW (g) 18.2±0.57 21.0±0.20 22.9±0.76* 19.9±0.58 22.5±0.57* 20.8±1.55
KW (g) 0.46±0.03 0.60±0.02* 0.66±0.07 0.79±0.10 1.18±0.06* 0.58±0.10**
KW % BW 2.54±0.13 2.85±0.07 2.85±0.25 3.95±0.40 5.23±0.27* 2.70±0.28**, *
Cyst Vv (%) ND ND ND 20.3±2.8 33.4±2.1* 17.4±5.05**
Total cyst volume (cc) ND ND ND 0.16±0.03 0.40±0.035* 0.10±0.04**
Cyst vol % BW ( 103) ND ND ND 8.1±1.4 17.6±1.5* 5.0±1.9**
Fibrosis score ND ND ND 2.1±0.2 2.7±0.2 1.6±0.2**
BUN (mg/100ml) 17.2±1.3 17.3±0.6 17.4±1.0 24.8±1.9 32.2±2.2* 22.9±1.4**
BUN, blood urea nitrgen; BW, body weight; Cyst Vv, cyst volume density; ND, not done; KW, kidney weight.
Mean±s.e.m.
*Pp0.05 for difference from treatment initiation age (6- or 20-week values).
**Pp0.05 for difference from age-matched control.
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Figure 2 | The kidneys from 30-week rapamycin-treated pcy mice exhibited less histopathological cystic change and fibrosis
(Picrosirius red (PSR) sections) than did 30-week control cystic kidney. There was generally less prominent renal cystic change and
fibrosis in the 30-week-treated kidney than in 20-week kidneys; however, generally these did not meet statistical significance. There was
little, if any, difference seen between the 12-week rapamycin-treated and 12-week control kidneys. H&E, hematoxylin and eosin stain.
180 Kidney International (2009) 76, 178–182
o r i g i n a l a r t i c l e VH Gattone et al.: Rapamycin ameliorates murine nephronophthisis
suggesting that treatment was able to cause some limited
degree of disease regression.
The use of slow release pellets containing the rapamycin
were very effective at inhibiting specifically stimulated mTOR
system. Rapamycin inhibited insulin stimulated phospho-
rylation of p70S6K in muscle without affecting the amount of
upstream phosphorylated AKT in wild-type mice (Figure 3).
The muscle system was used to evaluate the effectiveness of
the rapamycin pellets to avoid potential complications
associated with variability seen in this disease.
DISCUSSION
Nephronophthisis, although not as prevalent as ADPKD, is
an important cause of renal failure in the pediatric
population. Adolescent NPHP causes renal demise in
adolescence and to date there is no intervention for this
condition. This study found that rapamycin intervention in
the early stage of the disease did not inhibit the initial
development of cystic pathology; however, treatment with
rapamycin was efficacious in the later stage. At 20 weeks of
age, renal cystic pathology and fibrosis were already
significantly developed, yet rapamycin was able to inhibit
further pathology and functional deterioration. There was
even evidence that late-stage treatment caused some regres-
sion of the existing pathology present at 20 weeks of age. By
30 weeks, the cystic pathology and function deterioration had
progressed to a point where the efficacy of this treatment
could be clearly identified.
Rapamycin and/or other inhibitors of the mTOR pathway
have been shown to be efficacious in three different rodent
models, the Cy/þ rat,7–9 the bpk, and orpk mice.10 These
interventions were generally targeting the initial stages of the
cystic disease. The retrospective evaluation of renal transplant
patients with ADPKD who received rapamycin/sirolimus as
part of their immunosuppressive treatment also showed
inhibition of both renal and liver pathology.10,11 These
retrospective evaluations were clearly at late stages of the
ADPKD. Currently, there are prospective clinical trials using
mTOR inhibitors for the treatment of ADPKD (see Polycystic
Kidney Disease Foundation website on clinical trials, http://
www.pkdcure.org/). The determination of the efficacy of
rapamycin (or any treatment that will be proposed for
clinical trials) in orthologous rodent models of renal cystic
disease is important for determining at what stage(s) of the
disease the treatment would be most effective. Data currently
indicate that Octreotide, a somatostatin agonist, which is also
in clinical trials for PKD, may act through the same pathway
as mTOR inhibitors,13 suggesting that the mTOR pathway
may be part of the final common pathway involved in PKD
progression. To that end, this study has provided evidence
that the mTOR inhibitor rapamycin is efficacious in already
established renal cystic pathology of the pcy mouse model of
NPHP, but not effective in the early stage of this rodent form
of renal cystic disease.
Most interventions that have been evaluated in rodent
models are aimed at the initial stages of the cystic disease;
however, many of the affected patients may not even be
diagnosed until they already have significant pathology, being
more analogous to our 20-week pcy mouse. The identifica-
tion of interventions that are efficacious at more advanced
stages of the renal cystic disease could be very valuable.
Although it is evident that some aspects of the renal
pathology were already well established when treatment was
initiated and may be irreversible, it also seems that some
aspects of the pathology are not only stopped, but may even
be reversed with treatment. This seems evident from our pcy
mouse study and is also suggested by retrospective human
ADPKD studies.10,11 A similar reversal of renal cystic
pathology in rodents was observed with one other treatment,
vasopressin V2 receptor antagonism, in the pcy mouse.6
However, the prospect of reversing later stage renal and liver
cystic disease may ultimately be the goal of any treatment for
these conditions.
MATERIALS AND METHODS
Studies were conducted at the Indiana University School of
Medicine with a colony of CD1-pcy/pcy mice and all the procedures
were approved by the IACUC. Male pcy/pcy and age-matched
normal CD1 mice were used in this study. Western blot was used to
evaluate activity of the mTOR pathway in pcy mice, as compared
with the age-matched wild-type CD1 mice. Total and phosphory-
lated Akt and p70S6K, as well as phosphorylated ERK (known to be
elevated in the cystic kidney, especially in the cysts12) were
evaluated. The mice were anesthetized (sodium pentobarbital
100 mg/kg), kidneys were removed, snap frozen in liquid nitrogen,
homogenized, measured for total protein, and equal amounts of
protein were electrophoresed in acrylamide gels. Immunoblots for
total and phosphorylated PKB (Akt), and p70S6K as well as
phosphorylated ERK were carried out to evaluate activation of the
mTOR pathway. The primary antibodies used for western blots were
from Upstate Biotechnology (LakePlacid, NY, USA) and the
peroxidase secondary antibody was from Vector Laboratories
(Burlingame, CA, USA).
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Figure 3 | Immunoblots for phosphorylated PKB (Akt) and
p70S6K were carried out in insulin-stimulated skeletal muscle
to evaluate the effect of the rapamycin slow-release pellets
and their dosage of rapamycin (approximately 3 mg/kg/day)
on mTOR activation. As expected, insulin induced activation of
PKB, regardless of the presence or absence of rapamycin, as it is
upstream from mTOR. Insulin-activated mTOR activity as evinced
by phosphorylated p70S6K, but only in the absence of rapamycin,
indicating that the rapamycin pellets successfully blocked
activation of mTOR and its downstream targets (for example,
p70S6K). Using an insulin-stimulated skeletal muscle system, the
rapamycin slow-release pellets were shown to be effective at
inhibiting a stimulated mTOR pathway.
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As it was apparent that the mTOR pathway was activated in the
pcy mouse, the efficacy of rapamycin to inhibit progression of the
renal cystic disease was assessed. Mice were either started on
treatment at 6 weeks of age (and terminated at 12 weeks to assess
the ability to slow the initial development of cystic renal enlargement)
or 20 weeks of age (and terminated at 30 weeks to assess the ability of
the treatment to slow, or stop cystic pathology progression after it was
already well established). Treatment was accomplished using slow-
release pellets implanted subcutaneously (approximately 3 mg/kg/day
in 45 day slow-release pellets, Innovative Research of America, FL,
USA). Control groups included: (a) 6-week controls, (b) 12-week
controls, (c) 12-week rapamycin-treated, (d) 20-week controls, (e) 30-
week controls, (f) 30-week rapamycin-treated. As data from the
placebo-implanted and sham-implanted values were not different,
those groups were combined for 12- and 30-week control groups.
Mice were provided food (Teklad 7002, Harlan Lab, Indianapolis, IN,
USA) and water ad libitum and maintained on a 12 h:12 h, dark:light
cycle. At the time of killing killing, the mice were weighed,
anesthetized (sodium pentobarbital 100 mg/kg given i.p.), and the
blood was collected. A laparotomy was carried out and kidneys were
flushed with saline. The left kidney was weighed and then frozen in
liquid nitrogen. The right kidney was perfused with 4% paraformal-
dehyde in 0.1 M phosphate buffer, weighed, and transverse sections
were further immersion-fixed before processing for paraffin embed-
ment. Sera was assayed for urea nitrogen (Sigma Urea Assay kit #640,
Sigma Aldrich, St Louis MO, USA). Paraffin sections of the kidney
were stained (hemotoxylin/eosin or Picrosirius red), and random
regions of the cortex/outer medulla were photographed. The amount
of cystic change (cyst volume density (Vv)) was determined from
these random fields using point count stereology methods. The total
cyst volume was determined by multiplying cyst Vv (cc/cc) times the
kidney weight. Cyst volume as a percentage of total body weight was
determined by dividing the total cyst volume by total body weight.
Fibrosis was determined from 10–15 random fields on Picrosirius red-
stained slides using a 1þ to 4þ , minimal-to-severe, qualitative
score. The cystic epithelia were evaluated for proliferation (mitotic cell
index using morphological criteria for metaphase through telophase)
and apoptosis (apoptotic bodies) and expressed as a percentage. Data
were analyzed using analysis of variance for the group and, if
significant, individual comparison was made using analysis of
variance. Graphed and table data are expressed as mean±standard
error of the mean (s.e.m.).
To confirm the efficacy of the dose of rapamycin in the slow-
release pellets, the mTOR pathway was stimulated with insulin, and
the phosphorylation/activation of upstream and downstream
components were assessed using western blots in the skeletal
muscle. Briefly, wild-type mice with the slow-release rapamycin
pellets (implanted 2 weeks earlier) were injected i.p. with either
insulin or saline, 15 min before killing, and then anesthetized and
tibialis anterior muscle was removed, snap frozen in liquid nitrogen,
homogenized, measured for total protein, and electrophoresed in
acrylamide gels. Immunoblots for phosphorylated Akt, and p70S6K
were performed to evaluate activation of the mTOR pathway. As
expected, insulin induced activation of Akt, regardless of the
presence or absence of rapamycin. Insulin also activated the
downstream component of mTOR, phosphorylating p70S6K, but
only in the absence of rapamycin. The slow-release pellets of
rapamycin successfully blocked the activation of mTOR, evidenced
by the lack of phosphorylation of the downstream target (for
example, p70S6K). The skeletal muscle system was used, as we could
activate the mTOR pathway with insulin and show that rapamycin
could not inhibit this activation, independent of any changes
associated with the disease condition.
Note in proof
An MRI study on the efficacy of rapamycin in pcy mice, treated from
18 weeks to 28 weeks, is currently ‘in press’14 and confirms
rapamycin inhibition of renal cystic disease, even at this later stage
of disease in this model of NPHP.
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